Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21

Shokrollah Elahi, Robert H Weiss, Shahzma Merani

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: Antigen persistence due to HIV is a major source of inflammation and substantial immune activation, both of which are linked to accelerated aging. This illustrates the need to reduce immune activation in these patients and subsequently decrease the risk of cardiovascular diseases and other non-AIDS-defining comorbidities. Methods: CD4+ T cells were infected with HIV-1 isolates in the presence or absence of atorvastatin (0.25 to 1 mg/ml) for 24-48 h. Atorvastatin-induced anti-inflammatory functions and anti-viral replication were measured in vitro. Results: Atorvastatin, a lipid-lowering medication, exerted a broad spectrum of antiinflammatory functions by reducing T-cell immune activation markers (e.g. CD38, HLA-DR and Ki67), lowering HIV-1 co-receptor CCR-5, and decreasing proliferative capabilities of CD4+ T cells in vitro. In contrast, atorvastatin expanded regulatory T cells (Tregs) and upregulated the expression of T-cell immunoglobulin and ITIM domain (TIGIT), which enhanced the suppressive activity of Tregs. Furthermore, atorvastatin upregulated the cyclin-dependent kinase inhibitor p21, which is also known as cip-1 and waf-1, in the CD4+ T cells. Upregulation of p21 in CD4+ T cells rendered them less susceptible to HIV-1 infection and replication whereas siRNA-mediated p21 depletion and/or p21 selective inhibitor rescued viral replication. Interestingly, atorvastatin reduced HIV infection in both rested and phytohemagglutinin-activated CD4+ T cells in vitro. Finally, atorvastatin mediated p21 upregulation occurred via mevalonate pathway, but independent of p53. Conclusion: The results demonstrate a novel mechanism by which atorvastatin induced resistance of CD4+ T cells to HIV-1 infection via p21 upregulation and suggest that statins may hold particular promise for some HIV-infected individuals.

Original languageEnglish (US)
Pages (from-to)171-183
Number of pages13
JournalAIDS
Volume30
Issue number2
DOIs
StatePublished - 2016

Fingerprint

Up-Regulation
HIV
T-Lymphocytes
HIV-1
HIV Infections
CCR Receptors
Anti-Inflammatory Agents
Cyclin-Dependent Kinase Inhibitor p21
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Mevalonic Acid
Atorvastatin Calcium
Phytohemagglutinins
HLA-DR Antigens
Regulatory T-Lymphocytes
Small Interfering RNA
Comorbidity
Cardiovascular Diseases
Biomarkers
Inflammation
Lipids

Keywords

  • Atorvastatin
  • HIV infection
  • Mevalonate pathway
  • p21

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. / Elahi, Shokrollah; Weiss, Robert H; Merani, Shahzma.

In: AIDS, Vol. 30, No. 2, 2016, p. 171-183.

Research output: Contribution to journalArticle

Elahi, Shokrollah ; Weiss, Robert H ; Merani, Shahzma. / Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21. In: AIDS. 2016 ; Vol. 30, No. 2. pp. 171-183.
@article{b96806482dc547f3bf7649451a992738,
title = "Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21",
abstract = "Objective: Antigen persistence due to HIV is a major source of inflammation and substantial immune activation, both of which are linked to accelerated aging. This illustrates the need to reduce immune activation in these patients and subsequently decrease the risk of cardiovascular diseases and other non-AIDS-defining comorbidities. Methods: CD4+ T cells were infected with HIV-1 isolates in the presence or absence of atorvastatin (0.25 to 1 mg/ml) for 24-48 h. Atorvastatin-induced anti-inflammatory functions and anti-viral replication were measured in vitro. Results: Atorvastatin, a lipid-lowering medication, exerted a broad spectrum of antiinflammatory functions by reducing T-cell immune activation markers (e.g. CD38, HLA-DR and Ki67), lowering HIV-1 co-receptor CCR-5, and decreasing proliferative capabilities of CD4+ T cells in vitro. In contrast, atorvastatin expanded regulatory T cells (Tregs) and upregulated the expression of T-cell immunoglobulin and ITIM domain (TIGIT), which enhanced the suppressive activity of Tregs. Furthermore, atorvastatin upregulated the cyclin-dependent kinase inhibitor p21, which is also known as cip-1 and waf-1, in the CD4+ T cells. Upregulation of p21 in CD4+ T cells rendered them less susceptible to HIV-1 infection and replication whereas siRNA-mediated p21 depletion and/or p21 selective inhibitor rescued viral replication. Interestingly, atorvastatin reduced HIV infection in both rested and phytohemagglutinin-activated CD4+ T cells in vitro. Finally, atorvastatin mediated p21 upregulation occurred via mevalonate pathway, but independent of p53. Conclusion: The results demonstrate a novel mechanism by which atorvastatin induced resistance of CD4+ T cells to HIV-1 infection via p21 upregulation and suggest that statins may hold particular promise for some HIV-infected individuals.",
keywords = "Atorvastatin, HIV infection, Mevalonate pathway, p21",
author = "Shokrollah Elahi and Weiss, {Robert H} and Shahzma Merani",
year = "2016",
doi = "10.1097/QAD.0000000000000917",
language = "English (US)",
volume = "30",
pages = "171--183",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Atorvastatin restricts HIV replication in CD4+ T cells by upregulation of p21

AU - Elahi, Shokrollah

AU - Weiss, Robert H

AU - Merani, Shahzma

PY - 2016

Y1 - 2016

N2 - Objective: Antigen persistence due to HIV is a major source of inflammation and substantial immune activation, both of which are linked to accelerated aging. This illustrates the need to reduce immune activation in these patients and subsequently decrease the risk of cardiovascular diseases and other non-AIDS-defining comorbidities. Methods: CD4+ T cells were infected with HIV-1 isolates in the presence or absence of atorvastatin (0.25 to 1 mg/ml) for 24-48 h. Atorvastatin-induced anti-inflammatory functions and anti-viral replication were measured in vitro. Results: Atorvastatin, a lipid-lowering medication, exerted a broad spectrum of antiinflammatory functions by reducing T-cell immune activation markers (e.g. CD38, HLA-DR and Ki67), lowering HIV-1 co-receptor CCR-5, and decreasing proliferative capabilities of CD4+ T cells in vitro. In contrast, atorvastatin expanded regulatory T cells (Tregs) and upregulated the expression of T-cell immunoglobulin and ITIM domain (TIGIT), which enhanced the suppressive activity of Tregs. Furthermore, atorvastatin upregulated the cyclin-dependent kinase inhibitor p21, which is also known as cip-1 and waf-1, in the CD4+ T cells. Upregulation of p21 in CD4+ T cells rendered them less susceptible to HIV-1 infection and replication whereas siRNA-mediated p21 depletion and/or p21 selective inhibitor rescued viral replication. Interestingly, atorvastatin reduced HIV infection in both rested and phytohemagglutinin-activated CD4+ T cells in vitro. Finally, atorvastatin mediated p21 upregulation occurred via mevalonate pathway, but independent of p53. Conclusion: The results demonstrate a novel mechanism by which atorvastatin induced resistance of CD4+ T cells to HIV-1 infection via p21 upregulation and suggest that statins may hold particular promise for some HIV-infected individuals.

AB - Objective: Antigen persistence due to HIV is a major source of inflammation and substantial immune activation, both of which are linked to accelerated aging. This illustrates the need to reduce immune activation in these patients and subsequently decrease the risk of cardiovascular diseases and other non-AIDS-defining comorbidities. Methods: CD4+ T cells were infected with HIV-1 isolates in the presence or absence of atorvastatin (0.25 to 1 mg/ml) for 24-48 h. Atorvastatin-induced anti-inflammatory functions and anti-viral replication were measured in vitro. Results: Atorvastatin, a lipid-lowering medication, exerted a broad spectrum of antiinflammatory functions by reducing T-cell immune activation markers (e.g. CD38, HLA-DR and Ki67), lowering HIV-1 co-receptor CCR-5, and decreasing proliferative capabilities of CD4+ T cells in vitro. In contrast, atorvastatin expanded regulatory T cells (Tregs) and upregulated the expression of T-cell immunoglobulin and ITIM domain (TIGIT), which enhanced the suppressive activity of Tregs. Furthermore, atorvastatin upregulated the cyclin-dependent kinase inhibitor p21, which is also known as cip-1 and waf-1, in the CD4+ T cells. Upregulation of p21 in CD4+ T cells rendered them less susceptible to HIV-1 infection and replication whereas siRNA-mediated p21 depletion and/or p21 selective inhibitor rescued viral replication. Interestingly, atorvastatin reduced HIV infection in both rested and phytohemagglutinin-activated CD4+ T cells in vitro. Finally, atorvastatin mediated p21 upregulation occurred via mevalonate pathway, but independent of p53. Conclusion: The results demonstrate a novel mechanism by which atorvastatin induced resistance of CD4+ T cells to HIV-1 infection via p21 upregulation and suggest that statins may hold particular promise for some HIV-infected individuals.

KW - Atorvastatin

KW - HIV infection

KW - Mevalonate pathway

KW - p21

UR - http://www.scopus.com/inward/record.url?scp=84952981382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952981382&partnerID=8YFLogxK

U2 - 10.1097/QAD.0000000000000917

DO - 10.1097/QAD.0000000000000917

M3 - Article

C2 - 26645604

AN - SCOPUS:84952981382

VL - 30

SP - 171

EP - 183

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 2

ER -